摘要
近年来,我国医药产业作为国民经济的重要组成部分,得到了迅猛的发展。我国的"十二五"规划中,将医药产业中的生物医药作为战略性新兴产业来扶持,而医疗改革也使得医药产业成为社会关注的热点。以2007-2010年期间的140家制药行业上市公司的面板数据为样本,结合制药公司的行业特点,对公司规模、股权结构、技术创新等影响因素对于该行业上市公司的盈利能力进行实证研究。通过构建多元回归模型对影响因素的相关性进行排列,研究发现,股权集中度、公司规模、技术创新与盈利能力存在显著的正相关;法人股比例与盈利能力存在正相关;而国有股比例与盈利能力无关。最后本文就医药上市公司的股权集中度、技术创新和行业集中度三个方面给出政策建议。
In recent years, China＇s pharmaceutical industry, as an important part of the national economy, obtained the rapid de- velopment. In the ＂12th five-year plan＂ released by Chinese government, biological medicine industry has been treated as a strategic e- merging industry. Also, medical reform also makes medicine industry become a hot social issue. The article researches the pharmaceuti- cal industry＇s profit ability influencing factors based on the panel data of 140 pharmaceutical industry listing corporation from 2007 to 2010, combined with the industry characteristics of pharmaceutical enterprises, the company size, ownership structure and technical innovation. By constructing multivariate regression model to order the correlation of influencing factors, study finds, ownership concen- tration, the size of the company, technology innovation and profitability have significant positive correlation, the legal person share and profitability are related, and the proportion of state-owned shares has no effect on the profit ability. Finally, the suggestions of improv- ing the profit ability in pharmaceutical industry are given through three aspects： ownership structure, technical innovation and industry concentration.
出处
《技术经济与管理研究》
2013年第6期67-71,共5页
Journal of Technical Economics & Management
基金
福建省自然科学基金项目立项课题(2012J05129)
关键词
制药行业
上市公司
盈利能力
股权结构
Pharmaceutical industry
Listing corporation
Profit ability
Ownership structure
